Cullinan Therapeutics Inc (NASDAQ: CGEM) is 22.08% higher on its value in year-to-date trading and has touched a low of $7.64 and a high of $30.19 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CGEM stock was last observed hovering at around $12.96 in the last trading session, with the day’s loss setting it -0.52%.
Currently trading at $12.44, the stock is -10.16% and -18.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing -4.01% at the moment leaves the stock -31.58% off its SMA200. CGEM registered 47.39% gain for a year compared to 6-month loss of -44.81%. The firm has a 50-day simple moving average (SMA 50) of $15.4052 and a 200-day simple moving average (SMA200) of $18.20385.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -22.15% gain in the last 1 month and extending the period to 3 months gives it a -30.81%, and is -4.97% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.76% over the week and 7.06% over the month.
Cullinan Therapeutics Inc (CGEM) has around 85 employees, a market worth around $724.35M and $0.00M in sales. Distance from 52-week low is 62.83% and -58.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-22.82%).
The EPS is expected to grow by 17.78% this year
206.0 institutions hold shares in Cullinan Therapeutics Inc (CGEM), with institutional investors hold 124.38% of the company’s shares. The shares outstanding are 58.14M, and float is at 37.06M with Short Float at 23.50%. Institutions hold 118.79% of the Float.
The top institutional shareholder in the company is BIOIMPACT CAPITAL LLC with over 7.65 million shares valued at $133.39 million. The investor’s holdings represent 17.7821 of the CGEM Shares outstanding. As of 2024-06-30, the second largest holder is BVF INC/IL with 5.75 million shares valued at $100.29 million to account for 13.3703 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 3.55 million shares representing 8.2542 and valued at over $61.92 million, while DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) holds 7.6265 of the shares totaling 3.28 million with a market value of $57.21 million.
Cullinan Therapeutics Inc (CGEM) Insider Activity
The most recent transaction is an insider sale by Michaelson Jennifer, the company’s Chief Scientific Officer. SEC filings show that Michaelson Jennifer sold 8,000 shares of the company’s common stock on Nov 05 ’24 at a price of $15.64 per share for a total of $0.13 million. Following the sale, the insider now owns 0.11 million shares.
Cullinan Therapeutics Inc disclosed in a document filed with the SEC on Sep 05 ’24 that Michaelson Jennifer (Chief Scientific Officer) sold a total of 8,000 shares of the company’s common stock. The trade occurred on Sep 05 ’24 and was made at $18.09 per share for $0.14 million. Following the transaction, the insider now directly holds 0.12 million shares of the CGEM stock.
Still, SEC filings show that on Sep 05 ’24, JENNIFER MICHAELSON & MARC D M (Officer) Proposed Sale 16,000 shares at an average price of $18.68 for $0.3 million. The insider now directly holds shares of Cullinan Therapeutics Inc (CGEM).
